← Back to screener

Crinetics Pharmaceuticals, Inc. CRNX

Rank #2419 · Nasdaq · $8.8B market cap
Audited by BDO USA, P.C., no going-concern flag in the latest filing.
Score
19.6
P/E
-41.1
P/B
27.86
ROE
-67.8%
Op. Margin
-5547.2%
Debt Ratio
35%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -41.1x, P/B 27.86x. Ranks in the top 82% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -67.8%. Ranks in the top 94% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 35%. Ranks in the top 18% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 15.3% year over year. Ranks in the top 88% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2018$0.0B$-0.0B$-0.0B$-0.0B-1026.1-199
2019$0.0B$-0.0B$-0.0B$-0.0B-446.3-180
2020$0.0B$-0.0B$-0.0B$-0.0B-1182.5-88
2021$0.0B$-0.1B$-0.1B$0.2B-4512.39
2022$0.0B$-0.1B$-0.1B$0.1B-105567.616
2023$0.0B$-0.1B$-0.1B$0.2B-9990.921
2024$0.0B$-0.2B$-0.2B$0.3B-3544.129
2025$0.0B$-0.2B$-0.2B$0.3B-5547.235

← See the full screener